
==== Front
Invest New Drugs
Invest New Drugs
Investigational New Drugs
0167-6997
1573-0646
Springer US New York

38767685
1444
10.1007/s10637-024-01444-0
Correction
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
http://orcid.org/0000-0001-7012-1754
Armstrong Andrew J. andrew.armstrong@duke.edu

1
Geva Ravit 2
Chung Hyun Cheol 3
Lemech Charlotte 4
Miller Wilson H. Jr 5
Hansen Aaron R. 6
Lee Jong-Seok 7
Tsai Frank 8
Solomon Benjamin J. 9
http://orcid.org/0000-0001-6145-4426
Kim Tae Min 10
Rolfo Christian 11
Giranda Vincent 12
Ren Yixin 12
Liu Fang 12
http://orcid.org/0000-0001-5466-0897
Kandala Bhargava 12
Freshwater Tomoko 12
Wang Judy S. 13
1 grid.26009.3d 0000 0004 1936 7961 Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC 27710 USA
2 grid.12136.37 0000 0004 1937 0546 Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
3 https://ror.org/04sze3c15 grid.413046.4 0000 0004 0439 4086 Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea
4 Scientia Clinical Research, Randwick, NSW Australia
5 grid.414980.0 0000 0000 9401 2774 Segal Cancer Center, McGill University, Jewish General Hospital, Montreal, QC Canada
6 https://ror.org/03zayce58 grid.415224.4 0000 0001 2150 066X Princess Margaret Cancer Centre, Toronto, ON Canada
7 https://ror.org/00cb3km46 grid.412480.b 0000 0004 0647 3378 Seoul National University Bundang Hospital, Gyeonggi-Do, South Korea
8 grid.477855.c 0000 0004 4669 4925 Honor Health, Scottsdale, AZ USA
9 https://ror.org/02a8bt934 grid.1055.1 0000 0004 0397 8434 Peter MacCallum Cancer Centre, Melbourne, VIC Australia
10 https://ror.org/01z4nnt86 grid.412484.f 0000 0001 0302 820X Seoul National University Hospital, Seoul, South Korea
11 grid.516104.7 0000 0004 0408 1530 Center for Thoracic Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY USA
12 grid.417993.1 0000 0001 2260 0793 Merck & Co., Inc, Rahway, NJ USA
13 grid.428633.8 0000 0004 0504 5021 Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL USA
20 5 2024
20 5 2024
2024
42 3 340341
© The Author(s) 2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
issue-copyright-statement© Springer Science+Business Media, LLC, part of Springer Nature 2024
==== Body
pmcCorrection to: Investigational New Drugs (2024) 42:145-159 10.1007/s10637-023-01410-2

The article CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial, written by Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller Jr., Aaron R. Hansen, Jong‑Seok Lee, Frank Tsai, Benjamin J. Solomon, Tae Min Kim, Christian Rolfo, Vincent Giranda, Yixin Ren, Fang Liu, Bhargava Kandala, Tomoko Freshwater, Judy S. Wang, was originally published electronically on the publisher’s internet portal on February 7, 2024 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on March 24, 2024 to ©The Author(s) 2024 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Merck & Co., Inc., Rahway, NJ, USA and its affiliates and Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller Jr., Aaron R. Hansen, Jong-Seok Lee, Frank Tsai, Benjamin J. Solomon, Tae Min Kim, Christian Rolfo, Judy S. Wang 2024.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
